Aurinia Pharmaceuticals (AUPH) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Aurinia Pharmaceuticals Inc. presented new data at ASN Kidney Week 2024, highlighting the effectiveness of LUPKYNIS in treating lupus nephritis, particularly in diverse populations most affected by the disease. Real-world data showcased LUPKYNIS’s positive impact on kidney health compared to older therapies, with studies indicating improved outcomes and stronger podocyte stability at lower doses.
For further insights into AUPH stock, check out TipRanks’ Stock Analysis page.